Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

LSD-belegg av serotonin 2A-reseptoren i den menneskelige hjernen (dOccLS)

11. november 2026 oppdatert av: Gitte Moos Knudsen, Copenhagen University Hospital, Rigshospitalet

Lysergsyre-dietylamid Belegg av serotonin 2A-reseptoren i den menneskelige hjernen

The investigators wish to quantify the relation between administered dose of lysergic acid diethylamide (LSD), plasma LSD levels, and occupancy at the serotonin 2A receptor (5-HT2AR) using [11C]CIMBI-36 positron emission tomography.

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

Healthy participants will be administered one of a single dose of lysergic acid diethylamide (LSD) between 25 and 200 micrograms equivalent freebase. They will receive [11C]CIMBI-36 positron emission tomography (PET) scans at baseline and twice following LSD administration during peak and declining drug effects. PET scans will be acquired in a simultaneous PET/Magnetic Resonance Imaging (MRI) scanner which will also collect functional brain imaging data. Venous blood samples will be repeatedly drawn during acute drug effects for quantification of plasma LSD levels. Participants will also repeatedly rate their subjective drug intensity on a scale from 0 to 10 during acute drug effects. Together these data will inform the dose-binding relation of LSD at the serotonin (5-HT) 2A receptor, the primary site of action. This data will also inform the relation between 5-HT2A receptor binding by LSD and the induced subjective effects, as well as the effects on functional brain activity as measured with functional MRI.

Studietype

Intervensjonell

Registrering (Antatt)

40

Fase

  • Tidlig fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Gitte M Knudsen, DMsc, MD
  • Telefonnummer: +45 35456720
  • E-post: gmk@nru.dk

Studer Kontakt Backup

Studiesteder

      • Copenhagen, Danmark, 2100
        • Rekruttering
        • Neurobiology Research Unit, Rigshospitalet
        • Ta kontakt med:
          • Gitte M Knudsen, DMSc
          • Telefonnummer: +45 35456720
          • E-post: gmk@nru.dk
        • Underetterforsker:
          • Drummond E. McCulloch, BSc
        • Underetterforsker:
          • Patrick M. Fisher, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

• Healthy individual between 18-75 years old

Exclusion Criteria:

  • Current or past history of primary psychiatric illness (The Diagnostic and Statistical Manual of Mental Disorders IV axis-I or World Health Organisation International Classification of Diseases-10 diagnostic classification)
  • Current or past history of primary psychiatric illness (The Diagnostic and Statistical Manual of Mental Disorders IV axis-I or World Health Organisation International Classification of Diseases-10 diagnostic classification) in a first degree relative (i.e., parents, siblings)
  • Current or past history of neurological disease, significant somatic condition/disease
  • Use of medication that could potentially influence results (e.g.., drugs that act on relevant components of the serotonin system or may interfere with metabolism of study drug)
  • Non-fluent Danish language skills
  • Profound visual or auditory impairments
  • Severe learning disability
  • Pregnancy on the scan date, verified by a pregnancy test (test omitted if confirmed that individual is post-menopausal)
  • Lactation (females)
  • Contraindications for magnetic resonance imaging (e.g., pacemaker, claustrophobia, etc.)
  • Contraindications for positron emission tomography
  • Alcohol or drug abuse
  • Allergy to administered compounds
  • Participant in research study with >10 millisievert exposure within the past year or significant occupational exposure to radioactive substances
  • Abnormal ECG (ECG indicating current or previous heart disease or predisposition to heart disease, e.g., QT prolongation) or use of QT prolonging medication
  • Use of psychedelic substance within the preceding six months
  • Blood donation up to three months before the study (i.e., more than 500ml of blood)
  • Head injury or concussion resulting in loss of consciousness for more than 2 min
  • Haemoglobin levels < 7.8 mmol/l for women and 8.4 mmol/l for men
  • Ferritin levels outside normal range (12-300 µg/L)
  • Body-weight < 50 kg or > 110kg
  • body-mass index > 35
  • Individual assessment by research staff deeming drug administration unsafe due to ethical or psychological circumstance of the participant

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: LSD dose-ranging group

All participants will receive between 25 and 200 micrograms of lysergic acid diethylamide equivalent as freebase, single blinded with respect to dose. Simultaneous PET/MR imaging will be performed during acute drug effects.

D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)

Andre navn:
  • LSD
  • d-LSD
  • LSD-25

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Plasma LSD - serotonin 2A receptor (5-HT2AR) occupancy relation
Tidsramme: Within 24 hours following drug administration

Occupancy will be estimated by comparing non-displaceable binding potential (BPND) values using baseline and intervention rescans as calculated using a simplified reference tissue model (SRTM). Occupancy values will be compared to plasma lysergic acid diethylamide (LSD) levels.

Within 24 hours following drug administration

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Subjective drug intensity - 5-HT2AR occupancy relation
Tidsramme: Within 24 hours following drug administration

Occupancy will be calculated as described above. Subjective drug intensity is collected during positron emission tomography (PET) scans by asking participants.

Within 24 hours following drug administration
fMRI network disintegration - 5-HT2AR occupancy relation
Tidsramme: Within 24 hours following drug administration

functional magnetic resonance imaging (fMRI) data will be used to estimate functional-network connectivity using a standard functional brain atlas. Then the relation between decreases in functional network connectivity and 5-HT2AR occupancy will be estimated.

Within 24 hours following drug administration
fMRI brain entropy - 5-HT2AR occupancy relation
Tidsramme: Within 24 hours following drug administration

fMRI brain entropy will be estimated by the shannon entropy of dynamic conditional correlation of within and between network connectivity as well as the lempel-ziv complexity of concatenated binarised blood-oxygen level dependent (BOLD) signals across regions. The relation between each of these measures with 5-HT2AR occupancy will be estimated.

Within 24 hours following drug administration
Cerebral perfusion - 5-HT2AR occupancy relation
Tidsramme: Within 24 hours following drug administration

Cerebral perfusion will be estimated using arterial spin labelling. The relation between this measure and 5-HT2AR occupancy will be estimated.

Within 24 hours following drug administration
Administered LSD dose - 5-HT2AR occupancy relation
Tidsramme: Within 24 hours following drug administration

Administered dose (25 to 200 mcg) will be compared with peak LSD occupancy to determine what doses produce maximal occupancy at the 5-HT2AR.

Within 24 hours following drug administration

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Hysteresis effect of 5-HT2AR binding
Tidsramme: Within 24 hours following drug administration

Estimated dose-occupancy curves derived from the first PET scan and second PET scan will be calculated separately to evaluate whether there are differences in estimated plasma level-occupancy relation at different timepoints following LSD administration which may indicate a hysteresis effect due to peripheral LSD metabolism without unbinding of LSD from the 5-HT2A receptor.

Within 24 hours following drug administration

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Gitte M Knudsen, DMsc, MD, Copenhagen University Hospital, Rigshospitalet

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. november 2023

Primær fullføring (Antatt)

1. desember 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

14. februar 2023

Først innsendt som oppfylte QC-kriteriene

11. juli 2023

Først lagt ut (Faktiske)

19. juli 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere